IL-22 attenuates MAFLD progression by modulating oxidative stress and ferroptosis.

ABSTRACT: Metabolic-associated fatty liver disease (MAFLD) is a common liver disease in clinical practice and currently has limited standardized medications or treatments. The study aimed to evaluate the therapeutic effects of interleukin-22 (IL-22) on metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, and to explore its underlying molecular mechanisms. Male C57BL/6J mice were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for 12 weeks and treated with different doses of IL-22 intraperitoneally. IL-22 treatment significantly reduced hepatic lipid accumulation, suppressed hepatic stellate cell (HSC) activation, and prevented liver fibrosis. It also attenuated oxidative stress, evidenced by elevated SOD levels and reduced ROS, MDA levels. Meanwhile, changes in

SUBMITTER: Li S 

PROVIDER: S-EPMC12749523 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature